Latest News

Pharmaceutical industry engagement of patient advocates requires transparency about funding, conflicts of interest, and advocacy independence.

RFK Jr's Administration for a Healthy America proposes to dismantle infectious disease capacity while emphasizing unproven chronic disease theories.

Healthcare policy equality forms the foundation for LGBTQ+ liberation and health equity in prevention and treatment access.

Caregiving infrastructure supports health equity and healthcare outcomes, requiring policy investment in caregiving infrastructure.

CMS draft guidance on 340B claims modifiers creates ambiguity and enforcement gaps threatening program integrity and beneficiary access.

RFK Jr's budget testimony reveals plans to restructure HHS agencies and shift funding away from infectious disease prevention.

Antibiotic-resistant bacteria threaten basic medical procedures while drug development incentives prove inadequate for innovation.

Pharmacy benefit managers extract billions while adding no value, increasing costs without improving patient access or health outcomes.

Historical redlining policies correlate with current geographic disparities in HIV treatment access and care quality.

HHS budget proposal would eliminate critical HIV prevention funding and reduce Ryan White HIV/AIDS program resources.

Q2 2025 Watch monitoring HCV and HIV treatment access through ADAPs, Medicaid, and federal assistance.

Elimination of HIV data protections and surveillance capacity undermines disease tracking and outbreak response capability.

Trump administration's contradictory drug pricing policies undermine goals of affordability and innovation incentives.

Federal spending cuts disproportionately impact vulnerable populations relying on safety-net programs and community health services.

State Prescription Drug Affordability Boards limit public input while basing pricing decisions on flawed methodologies.

Deteriorating public health surveillance capacity creates blind spots for emerging disease threats and health disparities.

Long-acting injectable HIV treatments demonstrate clinical promise but face coverage and implementation barriers.

Copay accumulator programs exclude patient assistance from deductibles, creating barriers to medication adherence and treatment.

Declining vaccination rates and policy challenges create vulnerability to vaccine-preventable diseases and epidemic risk.

Convergence of influenza, avian flu, and tuberculosis threats reveals inadequate pandemic preparedness and disease response capacity.